Involvement of adipogenic potential of human bone marrow mesenchymal stem cells (MSCs) in osteoporosis

Current Stem Cell Research and Therapy

Volumn 3, Issue 3, 2008, Pages 208-218

  Pablo Rodriguez J ^a   Astudillo, Pablo ^a   Ríos, Susana ^a   Pino, Ana María ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Adipogenesis; Estrogens; Leptin; Mesenchymal stem cells; Osteogepesis; Osteoporosis; PPAR

Indexed keywords

AROMATASE; COLLAGEN TYPE 1; ESTRADIOL; ESTROGEN DERIVATIVE; LEPTIN; LIPID; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN C; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; ESTROGEN;

ADIPOCYTE; ADIPOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; ENZYME INACTIVATION; EXPERIMENTAL STUDY; HUMAN; LIPID STORAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; BONE MARROW CELL; MESENCHYMAL STEM CELL; METABOLISM; OSTEOPOROSIS; PATHOLOGY;

ADIPOGENESIS; BONE MARROW CELLS; CELL LINEAGE; ESTROGENS; HUMANS; MESENCHYMAL STEM CELLS; OSTEOPOROSIS;

EID: 52749090092     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488808785740325     Document Type: Review

References (136)

1. Caplan AI. Mesenchymal Stem Cells. J Orthop Res 1991; 9: 641-50.
2. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone 1992; 13: 81-8.
3. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997; 64: 278-94.
4. Gimble JM, Robinson CE, Wu X, Kelly KA. The function of adipocytes in the bone marrow stroma: An update. Bone 1996; 19: 421-8.
5. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders. J Bone Miner Res 1998; 13: 371-82.
6. Long MW, Robinson JA, Ashcraft EA, Mann KG. Regulation of human bone marrow-derived osteoprogfenitor cells by osteogenic growth factors. J Clin Invest 1995; 95: 881-7.
7. Lecanda F, Avioli LV, Cheng S-L. Regulation of bone matrix protein expression and induction of differentiation of human osteoblasts and human bone marrow stromal cells by bone morphogenetic protem-2. J Cell Biochem 1997; 67: 386-98.
8. American College of Obstetricians and Gynecologists. Osteoporosis. Obstet Gynecol 2004; 104; 66S-76S.
9. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. New England J Med 1995; 332: 305-11.
10. Compston J. Editorial: Local biosynthesis of sex steroids in bone. Journal of Clinical Endocrinol Metab 2002; 87: 5398-400.
11. Lin JT, Lane JM. Osteoporosis: a Review. Clin Orthop Relat R 2004; 425: 126-34.
12. Morales-Torres J, Gutiérrez-Ureña S. The Burden of Osteoporosis in Latin America. Osteoporos Int 2004; 15: 625-32.
13. Pittenger MF, Mackay AM, Beck SC, et al. Multineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
14. Jian Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murinc bone marrow, muscle, and brain. Exp Hematol 2002; 30: 896-904.
15. Keene CD, Ortiz-Gotizález XR, Jiang Y, Largaespada DA, Verfaillie CM, Low WC. Neural differentiation and incorporation of bone marrow-derived multipotent adult progenitor cells alter single cell transplantation into blastocyst stage mouse embryos. Cell transplant 2003; 12: 201-13.
16. Spees JL, Olson SD, Ylostalo J, et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc. Natl Acad Sci USA 2003; 100: 2397-402.
17. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficit after grafting into the ischemic brain of rats. Exp Neurol 2002; 174: 11-20.
18. Song L, Tuan RS. Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow. FASEB J 2004; 18: 980-2.
19. Song L, Webb NE, Song Y, Tuan RS. Identification and functional analysis of candidate genes regulating mesenchymal stem cells self-renewal and multipotency. Stem Cells 2006; 24: 1707-18.
20. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004; 8: 301-16.
21. Zipori D. The stem state: Plasticity is essential, whereas self-renewal and hierarchy are optional. Stem Cells 2005; 23: 719-26.
22. Zipori D. The stem state: Mesenchymal plasticity as a paradigm. Curr Stem Cell Res Ther 2006; 1: 95-102.
23. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med 2001; 226: 507-20.
24. Komori T. Regulation of Osteoblast Differentiation by Transcription Factors. J Cell Biochem 2006; 99: 1233-39.
25. Duey P, Zhang R, Geoffroy V, Riddall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89 747-54.
26. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrests of osteoblasts. Cell 1997; 89: 755-64.
27. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-71.
28. Liu W, Toyosawa S, Furuichi T, et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblasts maturation and causes osteopenia with multiple fractures. J Cell Biol 2001; 155: 157-66.
29. Geoffroy V, Kneissel M, Fournier B, Boyde A, Matthias P. High bone resorption in adult aging transgenic mice overexpressmig cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 2002; 22: 6222-33.
30. Nishimura R, Hata K, Harris SE, Ikeda F, Yoneda T. Core-binding factor alpha 1 (Cbfa1) induces osteoblastic differentiation of C2C12 cells without interactions with Smad1 and Smad5. Bone 2002; 31: 303-12.
31. Zheng H, Guo Z, Ma Q, Jia H, Dang G. Cbfa1/osf2 transduced bone marrow stromal cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int 2004; 74: 194-203.
32. Zhao Z, Zhao M, Xiao G, Franceschi RT. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 2005; 12: 247-53.
33. Stein GS, Lian JB, van Wijnen AJ, et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004; 23: 4315-29.
34. Lian JB, Stein JL, Stein GS, et al. Runx2/Cbfa1 Functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connec Tissue Res 2003; 44: 141-8.
35. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 17-29.
36. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/βcatenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005; 8: 739-50.
37. Hill TP, Sparer D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/ b-catenin signaling prevents ostooblasts from differentiating into chondrocytes. Dev Cell 2005; 8: 727-38.
38. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Writ signaling in osteoblast development. Development 2005; 132: 49-60.
39. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
40. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-4.
41. Rosen ED, Spiegelman BM. PPARg: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 12: 37731-4.
42. Saladin R, Fajas L, Dana S, Halvorsen Y, Auwerx J, Briggs M. Differential regulation of Peroxisome Proliferator Activated Receptor γ1 (PPARγ1) and PPARγ2 messenger RNA expresión in the early stages of adipogénesis. Cell Growth Differ 1999; 10: 43-8.
43. Barak Y, Nelson MC, Ong ES, et al. PPARγ is required for placental, cardiac and adipose tissue development. Mol Cell 1999; 4: 585-95.
44. Rosen ED, Sarraf P, Troy AE, et al. PPARγ is required for the differentiation of adipose tissue In vivo and In vitro. Mol Cell 1999; 4: 611-7.
45. Lowell BB. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 1999; 99: 239-42.
46. Rangwala S, Lazar MA. Transcriptional Control of Adipogenesis. Annu Rev Nutr 2000; 20: 535-59.
47. Lee C, Olson P, Evans RM. Minireview: Lipid Metabolism, Metabolic diseases, and Peroxisome Proliferator-Activated Receptors. Endocrinology 2003; 144: 2201-7.
48. Kota BP, Huang TH, Roufogalis BD. An overview of biological mechanisms of PPARs. Pharm Res 2005; 51: 85-94.
49. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR-gamma. Science 1996; 274: 2100-3.
50. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18: 1842-53.
51. Chan GK, Deckelbaum RA, Bolivar I, Goltzman D, Karaplis AC. PTHrP inhibits adipocyte differentiation by down-regulating PPAR gamma activity via a MAPK-dependent pathway. Endocrinology 2001; 142: 4900-9.
52. Aouanadi M, Laurent K, Prot M, Le Marchand-Brustel Y, Binétruy B, Bost F. Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes 2006; 55: 281-9.
53. Diradourian C, Girard J, Pégorier J P. Phosphorylation of PPARs: from molecular characterization to physiological relevance Biochimie 2005; 87: 33-8.
54. Ikehara S. A new concept of stem cell disorders and their new therapy. J Hematother Stem Cell Res 2003; 12: 643-53.
55. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1971; 80: 147-54.
56. Ogawa S, Urano T, Hosoi T, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 1999; 260: 122-6.
57. Bodine PV, Zhao W, Kharode YP, et al. The Wnt antagonist secreted frizzled related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 2004; 18: 1222-37.
58. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 2005; 102: 3324-9.
59. Bennett JH, Joyner, CJ, Triffitt JT, Owen ME. Adipocytic cells cultured from marrow have osteogenic potential. J Cell Sci 1991; 99: 131-9.
60. Ji X, Chen D, Xu C, Harris SE, Mundy GR, Yoneda T. Patterns of gene expression associated with BMP-2- induced osteoblast and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A. J Bone Miner Metab 2000; 18: 132-9.
61. Wronski TJ, Walsh CC, Ignaszewski LA. Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 1986; 7: 119-23.
62. Moerman EJ, Teng K, Lipschitz DA, Locka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell 2004; 3: 379-89.
63. Minaire P, Meunier P, Edouard C, Bernard J, Courpron P, Bourret J. Quantitative histological data on disuse osteoporosis: comparison with biological data. Calcif Tissue Res 1974; 17: 57-73.
64. Zayzafon M, Gathings WE, McDonald JM. Modeled microgravity inhibits osteogenic differentiation of human mesenchymal stem cells and increases adipogenesis Endocrinology 2004; 145: 2421-32.
65. Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999; 42: 920-5.
66. Glass 2nd DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751-64.
67. Lecka-Czernik B, Gubrij I, Moerman EA, et al. Inhibition of Osf2/ Cbaf1 expression and terminal osteoblast differentiation by PPAR-gamma.2. J Cell Biochem 1999; 74: 357-71.
68. Jeon MJ, Kim JA, Kwon SH, et al. Activation of Peroxisome Proliferator-activated Receptor-γ inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003; 278: 23270-7.
69. Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-γ inhibits differentiation of preosteoblasts. J Lab Clin Med 2003; 142: 29-34.
70. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145: 401-6.
71. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007; 148: 2669-80.
72. Klein RF, Allard J, Avnur Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004; 303: 229-32.
73. hyp/hyp mice relocateshaematopoiesis tothe spleen. EMBO reports 2004; 5: 1007-12.
74. Kobayashi H, Gao Y, Ueta C, Yamaguchi A, Komori T. Multiline-age differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun 2000; 273: 630-6.
75. Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289: 950-3.
76. Kennell JA, O'Leary EE, Gummow BM, Hammer GD, MacDougald OA. T-cell factor 4N (TCF-4N), a novel isoform of mouse TCF-4, synergizes with beta-catenin to coactivate C/EBPalpha and steroidogenic factor 1 transcription factors. Mol Cell Biol 2003; 23: 5366-75.
77. Moldes M, Zuo Y, Morrison RF, et al. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/ beta-catenin signalling during adipogénesis. Biochem J 2003; 376: 607-13.
78. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of β-catenin in postnatal bone acquisition. J Biol Chem 2005; 280: 21162-8.
79. Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in Osteopenia. Bone 2006; 39: 754-66.
80. Qiu W, Andresen TE, Bollerslev J, Mandrup S, Abdallah BM, Kassem M. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogénesis of human mesenchymal stem cells. J Bone Min Res 2007; 22: 1720-31.
81. Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early post menopausal women. J Clin Endocrinol Metab 1997; 82: 414-7.
82. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001; 2: 165-71.
83. Smith EC, Boyd J, Franck GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. New England J Med 1994; 331: 1056-61.
84. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 86: 3689-98.
85. Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Int Med 2000; 133: 951-63.
86. Khosla S, Melton III LJ, Atkinson EJ, O'Fallon WM. Relationship of sex steroids to longitudinal changes in bone mineral density and bone resorption in young versus elderly men: effects of estrogen on peak bone mass and on age-related bone loss. J Clin Endocrinol Metab 2001; 86: 3555-61.
87. Schweikert HU, Rulf W, Niederle N, Schafer HE, Keck E, Krück F. Testosterone metabolism in human bone. Acta Endocrinologica 1980; 95: 258-64.
88. Schweikert HU, Wolf L, Romalo G. Oestrogen formation from androstenedione in human bone. Clin Endocrinol (Oxf) 1995; 43: 37-42.
89. Janssen JMMF, Bland R, Hewison M, et al. Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J Cell Biochem 1999; 75: 528-37.
90. Ishida Y, Killinger DW, Khalil MW, Yang K, Strutt B, Heersche JN. Expression of steroid-converting enzymes in osteoblasts derived from rat vertebrae. Osteopor Int 2002; 13: 235-40.
91. Issa S, Schnabel D, Feix M, et al. Human osteoblas-like cells express predominantly steroid 5α-reductase type 1. J Clin Endocrinol Metab 2002; 87: 5401-7.
92. Heim M, Frank O, Kampmann G, et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 2004; 145: 848-59.
93. Purohit A, Flanagan AM, Reed MJ. Estrogen synthesis by osteoblast cell lines. Endocrinology 1992; 131: 2027-9.
94. Tanaka S, Haji M, Nishi Y, Yanase T, Takayanagi R, Nawata H. Aromatase activity in human osteoblast-like osteosarcoma cell. Calcified Tiss Int 1993; 52: 107-9.
95. Sasano, H, Uzuki M, Sawai T, et al. Aromatase in human bone tissue. J Bone Min Res 1997; 12: 1416-23.
96. Shozu M, Zhao Y, Simpson ER. Estrogen biosynthesis in THP-1 cells is regulated by promoter switching of the aromatase (CYP19) gene. Endocrinology 1997; 138: 5125-35.
97. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci USA 2000; 97: 12729-34.
98. Jones ME, Thorburn AW, Britt KN, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci USA 2000; 97: 12735-40.
99. Okazaki R, Inoue D, Shibata M, et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow estromal cell lines that express estrogen receptor (ER)α or β. Endocrinology 2002; 143: 2349-56.
100. Pino AM, Rodríguez JM, Ríos S, et al. Aromatase activity of human mesenchymal stem cells is stimulated by early differentiation, vitamin D and leptin. J Endocrinol 2006; 191: 715-25.
101. Riggs BI, Khosla S, Melton III LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
102. Gennari L, Nuti R, Bilezikian JP. Aromatase activity and bone homeostasis in men. J Clin Endocrinol Metab 2004; 89: 5898-907.
103. Bianco P, Robey PG. Diseases of bone and stromal cell lineage. J Bone Miner Res 1999; 14: 336-41.
104. Rodríguez, JP, Garat, S, Gajardo, H, Pino, AM, Seitz, G. Abnormal osteogenesis in osteoportic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem 1999; 75: 414-23.
105. Rodríguez JP, Montecinos L, Ríos S, Reyes P, Martínez J. Mesenchymal Stem Cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem 2000; 79: 557-65.
106. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified culture-explanded human mesenchymal stem cells in vitro. J Cell Biochem 1997; 64: 295-312.
107. Prusty D, Park B-H, Davis KE, Farmer SR. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferators-activated receptor g (PPARg) and C/EBPa gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem 2002; 277: 46226-32.
108. Bergman RJ, Gazit D, Kahn AJ, Gruber H, McDougall S, Hahn TJ. Age-related changes in osteogenic stem cells in mice. J Bone Miner Res 1996; 11: 568-77.
109. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med 1996; 334: 292-5.
110. Thomas T, Burguera B, Melton LJ III, Atkinson EJ, Riggs BL, Khosla S. Relationship of serum leptin levels with body composition, sex steroid, and insulin levels in men and women. Metabolism 2000; 49: 1278-84.
111. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006; 2: 35-43.
112. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Min Res 2002; 17: 1563-9.
113. Glauber HS, Vollmer WM, Nevitt MC, Ensrud KE, Orwoll ES. Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab 1995; 80: 1118-23.
114. Khosla S, Atkinson EJ, Riggs BL, Melton LJ. Relationship between body composition and bone mass in women. J Bone Min Res 1996; 11: 857-63.
115. Isaia GC, D'Amelio P, Di Bella S, Tamone C. Is leptin the link between fat and bone mass? J Endocrinol Invest 2005; 28(10 Suppl): 61-5.
116. Karsenty G. Leptin control bone formation through a hypothalamic relay. Rec Prog Horm Res 2001; 56: 401-15.
117. Thomas T, Gori F, Khosla S, Jensen M D, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630-8.
118. Hess R, Pino AM, Rios S, Fernández M, Rodríguez JP. High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cell Biochem 2005; 94: 50-7.
119. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272: 6093-6.
120. Reseland JE, Syversen U, Bakke I, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Min Res 2001; 16: 1426-33.
121. Holloway WR, Collier FMcL, Aitken CJ, et al. Leptin inhibits Osteoclast Generation. J Bone Min Res 2002; 17: 200-9.
122. Takahashi Y, Okimura Y, Mizuno I, et al. Leptin induce mitogen-activated protein kinase-dependent proliferation of C3H10T1/2 cells. J Biol Chem 1997; 272: 12897-900.
123. Lai CF, Chaudhary L, Fausto A, et al. Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 2001; 276: 14443-50.
124. Astudillo P, Ríos S, Pastenes L, Pino AM, Rodríguez JP. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem 2007, Published Online: 31 Oct 2007, DOI: 10.1002/jcb.21516.
125. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferators-activated receptor gamma. J Biol Chem 1998; 273: 1855-8.
126. Waite KJ, Floyd ZE, Arbour-Reily P, Stephens JM. Interferon-γ-induced regulation of peroxisome proliferators-activated receptor γ and STATs in adipocytes. J Biol Chem 2001; 276: 7062-68.
127. Kallen CB, Lazar MA. Antidiabetic thiazolidinedione inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996; 93: 5793-6.
128. Sabatakos G, Sims NA, Chen J, et al. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 2000; 6: 985-90.
129. Patel NG, Holder JC, Smith SA, Kumar S, Eggo MC. Differential regulation of lipogenesis and leptin production by independent signaling pathways and rosiglitazone during human adipocyte differentiation. Diabetes 2003; 52: 43-50.
130. Unger RH. Lipid overload and overflow: Metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398-403.
131. Bjorbaek C, Lavery HJ, Bates SH, et al. SOCS-3 mediated feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 2000; 275: 40649-57.
132. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006; 17: 144-9.
133. Casabiell X, Pineiro V, Peino R, et al. Gender differences in both spontaneous and stimulated leptin secretion by human omental adipose tissue in vitro: dexamethasone and estradiol stimulate leptin release in women, but not in men. J Clin Endocrinol Metab 1998; 83: 2149-55.
134. Cheng GA, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase IB. Dev Cell 2002; 2: 497-503.
135. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP-1B regulates leeptin signal transduction in vivo. Dev Cell 2002; 2: 489-95.
136. Rodríguez JP, Ríos S, Fernández M, Santibañez JF. Differential activation of ERK1,2 MAP kinase signaling pathway in mesenchymal stem cell from control and osteoporotic postmenopausal women. J Cell Biochem 2004; 92: 745-754.